CORDIS
EU research results

CORDIS

English EN
Nanotherapeutics for antibiotic resistant emerging bacterial pathogens

Nanotherapeutics for antibiotic resistant emerging bacterial pathogens

Objective

Increase in antibiotic resistance is a global concern worldwide. The project NAREB's main objective is the optimization of several nanoformulations of antibacterial therapeutics in order to improve the therapy of multi-drug resistant (MDR) tuberculosis (TB) and MRSA infections in European MDR patients.

NAREB will address the problem of drug bioavailability inside the infected macrophages, transport across the bacterial cell wall, and avoidance of escape mechanisms (expressed by the pathogen). The success of the utilization of nanoparticles in the improvement of drug targeting in other diseases opens the way for novel applications in nanotechnology-based treatments aimed at controlling MDR-TB and MRSA.

Specific objectives to achieve the main goal are:
(i) Screening of different combinations of antibiotic drugs (small chemical molecules and/or biomacromolecules - glycopeptides) with nanocarriers (lipid, polymeric, biopolymeric);
(ii) Loading of Transcription Factor Decoys (TFDs) designed to block the expression of essential bacterial genes in compatible nanoparticle systems and their testing as novel antibacterials;
(iii) In vitro and in vivo testing of the best therapeutic combinations in relevant experimental models and using innovative bioimaging;
(iv) Improved formulations of multifunctional particles containing selected antibiotics and TFDs for increasing the bioavailability of active molecules in the site of infection (targeting strategy, adapted route of administration)
(v) Assessing safety, regulatory and production (GLP/GMP) aspects in relation with the most promising nanoformulations;
(vi) Clinical Development Plan for the preparatory work for the subsequent clinical testing of the selected nanoformulations.

The project NAREB brings together 15 partners (including 4 SMEs and 1 industry) from 8 EU Member and Associated States with outstanding complementary expertise, ranging from material engineering to molecular biology, pharmacology and medicine.
Leaflet | Map data © OpenStreetMap contributors, Credit: EC-GISCO, © EuroGeographics for the administrative boundaries

Coordinator

INSTITUT PASTEUR

Address

Rue Du Docteur Roux 25-28
75724 Paris Cedex 15

France

Activity type

Research Organisations

EU Contribution

€ 1 576 873,80

Administrative Contact

Sophie Ablott

Participants (15)

Sort alphabetically

Sort by EU Contribution

Expand all

COMMISSARIAT A L ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES

France

EU Contribution

€ 968 521

UNIVERSITEIT UTRECHT

Netherlands

EU Contribution

€ 370 802

PROCARTA BIOSYSTEMS LIMITED

United Kingdom

EU Contribution

€ 344 065

UNIVERSIDAD DE ZARAGOZA

Spain

EU Contribution

€ 765 614

National Medicines Institute (Narodowy Instytut Lekow)

Poland

EU Contribution

€ 213 262

FORSCHUNGSZENTRUM BORSTEL

Germany

EU Contribution

€ 363 466

BIOASTER FONDATION DE COOPERATION SCIENTIFIQUE

France

EU Contribution

€ 858 776,20

Medicines and Healthcare products Regulatory Agency

United Kingdom

EU Contribution

€ 79 849

GLAXOSMITHKLINE INVESTIGACION Y DESARROLLO SL

Spain

EU Contribution

€ 810 480

CORIS BIOCONCEPT SPRL

Belgium

EU Contribution

€ 512 824

NANOIMMUNOTECH SL

Spain

EU Contribution

€ 1 019 702

STIFTELSEN SINTEF

Norway

EU Contribution

€ 845 282

INSERM TRANSFERT SA

France

EU Contribution

€ 479 044

KUECEPT LIMITED

United Kingdom

EU Contribution

€ 227 528

UNIVERSITY OF EAST ANGLIA

United Kingdom

EU Contribution

€ 238 069

Project information

Grant agreement ID: 604237

Status

Closed project

  • Start date

    1 February 2014

  • End date

    31 July 2018

Funded under:

FP7-NMP

  • Overall budget:

    € 13 077 695,60

  • EU contribution

    € 9 674 158

Coordinated by:

INSTITUT PASTEUR

France